The single nucleotide polymorphisms in BRAP decrease the risk of metabolic syndrome in a Chinese young adult
Lijun Wu1, Bo Xi, Dongqing Hou
1Department of Epidemiology, Capital Institute of Pediatrics, Beijing, People's Republic of China.
Diabetes & Vascular Disease Research
|September 12, 2012
Summary
Single nucleotide polymorphisms (SNPs) in the BRAP gene are linked to a reduced risk of metabolic syndrome (MetS). These BRAP gene variations also associate with key MetS components like waist circumference and plasma glucose.
Area of Science:
- Genetics
- Cardiovascular Disease
- Metabolic Health
Background:
- Single nucleotide polymorphisms (SNPs) in the BRCA1-associated protein (BRAP) gene are linked to coronary artery disease.
- The molecular mechanisms underlying this association are not fully understood.
- Metabolic syndrome (MetS) is a significant predictor of cardiovascular disease.
Purpose of the Study:
- To investigate the association between specific BRAP gene SNPs (rs11066001 and rs3782886) and metabolic syndrome (MetS).
- To explore potential links between these BRAP SNPs and factors related to inflammation.
- To elucidate the role of BRAP gene variations in cardiovascular health.
Main Methods:
- Examined the associations of BRAP SNPs (rs11066001 and rs3782886) with MetS.
- Utilized a dominant genetic model after adjusting for age and gender.
- Assessed associations with individual MetS components, including waist circumference, plasma glucose, glycated hemoglobin, triglycerides, and nonesterified fatty acid.
Main Results:
- Both rs11066001 and rs3782886 in the BRAP gene showed significant associations with a reduced risk of MetS (OR 0.70, p=0.028; OR 0.69, p=0.020, respectively).
- Significant associations were observed between these SNPs and several MetS components: waist circumference, plasma glucose, glycated hemoglobin, triglycerides, and nonesterified fatty acid.
- The study identified distinct associations of the SNPs with various MetS components.
Conclusions:
- BRAP gene SNPs rs11066001 and rs3782886 are associated with a decreased risk of developing metabolic syndrome.
- These genetic variations in BRAP may influence key metabolic factors, including nonesterified fatty acid levels, potentially impacting inflammatory processes.
- The findings contribute to understanding the genetic underpinnings of MetS and cardiovascular disease risk.
More Related Videos
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:26Comparing Copy Number Variations and SNPs
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...